PD-1/PVRIG/TIGIT Binding Protein Composition for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody drugs, such as anti-PD-1, TIGIT, and PVRIG antibodies, face challenges due to their large molecular weights and complex structures, leading to instability and degradation, which affects their efficacy in cancer immunotherapy.
Innovation Solution
A pharmaceutical composition comprising a PD-1/PVRIG/TIGIT-binding protein, stabilized by a citrate or histidine buffer, with specific antigen-binding domains for PD-1, PVRIG, and TIGIT, enhancing stability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibody drugs are used for cancer immunotherapy, then therapeutic efficacy is improved, but stability and degradation resistance deteriorate due to large molecular weight and complex structure
Solution Approach 1:
The patent segments the large antibody molecule into smaller binding proteins that specifically target PD-1, PVRIG, and TIGIT. This segmentation reduces molecular weight and complexity while maintaining therapeutic efficacy through targeted immune checkpoint inhibition, thereby improving stability without sacrificing reliability
Solution Approach 2:
The patent changes the molecular parameters by developing binding proteins with optimized molecular weights and structural configurations. These parameter changes reduce the complexity-associated instability of full-size antibodies while preserving the immunotherapeutic function through specific binding to immune checkpoint receptors
2Reliability
If multiple immune checkpoint targets (PD-1, PVRIG, TIGIT) are addressed simultaneously, then therapeutic efficacy is improved, but device complexity increases
Solution Approach 1:
The patent merges multiple binding specificities into a single composition by combining binding proteins that target PD-1, PVRIG, and TIGIT. This merging approach achieves multi-target immunotherapy efficacy while managing complexity through a unified pharmaceutical formulation rather than separate treatments
Solution Approach 2:
The binding proteins in the composition exhibit multi-functionality by simultaneously addressing multiple immune checkpoint pathways (PD-1, PVRIG, TIGIT). This universality allows a single composition to perform multiple therapeutic functions, improving efficacy without proportionally increasing complexity
Data Source
Figure 1A~1B
Figure 2~3A
Figure 3B~4
AI summary
The present disclosure relates to a pharmaceutical composition containing a PD-1/PVRIG/TIGIT binding protein and a medical use thereof. Specifically, the pharmaceutical composition involved in the present disclosure contains a PD-1/PVRIG/TIGIT binding protein and a buffering agent. The pharmaceutical composition of the present disclosure has good biological activity and stability.